Sponsor Dossier
Bristol-Myers Squibb
Sponsor Dossier for Bristol-Myers Squibb. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: APIXABAN-APX
- Brand: AUGTYRO
- Brand: CAMZYOS
- Brand: ELIQUIS
- Brand: EMPLICITI
- Brand: EVOTAZ
- Brand: INREBIC
- Brand: Istodax
About
Bristol-Myers Squibb is an Australian Private Company with ABN 33004333322, registered in Victoria. The company is active and registered for GST.
Portfolio
Bristol-Myers Squibb has 24 brands on the ARTG, of which 23 are indexable and 21 carry a Product Information document. 18 brands are PBS-listed, 17 have a PBAC outcome on record, and 18 have an AusPAR on record. Notable brands include APIXABAN-APX, AUGTYRO, CAMZYOS, ELIQUIS, EMPLICITI, EVOTAZ, INREBIC, Istodax, NULOJIX, ONUREG, OPDIVO, OPDUALAG.
Therapeutic focus
— Oncology: 13 brands — Cardiology: 3 brands — Immunology: 2 brands — Haematology: 2 brands — Infectious Disease: 2 brands — Neurology: 1 brand — Dermatology: 1 brand
PBS footprint
18 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-05-01, across 17 brands with a PBAC outcome on record. The latest AusPAR is 2026-02-02, across 18 brands with an AusPAR on record.